Are CSL shares worth buying after its latest deal?
AI Market Summary
CSL announced a major drug-development partnership with Alentis for a Claudin-1 targeted therapy in Phase II for a rare autoimmune kidney disease. The deal includes a US$355m upfront payment plus CSL funding ongoing development, with a 55/45 global profit split if commercialized. The news is incrementally constructive for pipeline optionality but introduces near-term deal cost and clinical/regulatory execution risk for CSL shares.
Impact level
● Medium
Affected assets
NCSKCSCL2USD/USDT+2.31%
AI Insight · NCSKCSCL2USD/USDTAI Insight
● Neutral
Trade now
⚠️ AI-generated insights are based on news content and are provided for informational purposes only. They do not constitute investment advice or represent the views of BingX. Investing involves risk. Please trade responsibly.
CSL Limited has struck a major drug-development partnership with Alentis for an experimental therapy targeting Claudin-1. The candidate is currently in a Phase II trial for a rare autoimmune kidney disease.
Under the agreement, CSL will pay an upfront US$355 million and fund the costs of the subsequent development program. If the drug reaches the market, CSL will receive 55% of global profits, with Alentis taking 45%.
CSL shares were trading around A$177 on Tuesday. Based on consensus forecasts for FY27 to FY29 earnings per share of A$8.99 to A$10.08, the stock is valued at about 20 times earnings, easing to roughly 17.5 times on the same estimates.
